U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.55
    +0.12 (+0.11%)
     
  • Gold

    1,811.00
    +9.50 (+0.53%)
     
  • Silver

    19.75
    +0.08 (+0.40%)
     
  • EUR/USD

    1.0441
    +0.0014 (+0.1357%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2125
    +0.0022 (+0.1831%)
     
  • USD/JPY

    135.4710
    +0.2960 (+0.2190%)
     
  • BTC-USD

    19,110.54
    +7.22 (+0.04%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,242.74
    +74.09 (+1.03%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Adagene to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42nd Annual Global Healthcare Conference to be held June 8-11, 2021.

Details on the presentations can be found below.

Jefferies Virtual Healthcare Conference
Date: Friday, June 4, 2021
Presentation Time: 10:00 AM ET
Webcast: Click Here

Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Thursday, June 10, 2021
Presentation Time: 5:30 PM ET
Webcast: Click Here

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Investors Contact:
Raymond Tam
Adagene
86-512-8777-3626
ir@adagene.com

Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

Media Contact:
Annie Starr
6 Degrees
973-768-2170
astarr@6degreespr.com